Clinical and epidemiological research
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1
Jump to comment:
In his comments about our INFAST trial (1) H Zeidler addresses the question whether a separation in patients with predominant axial and with predominant peripheral spondyloarthritis (SpA) manifestations makes sense and whether it reflects realitiy. Peripheral arthritis is one of the clinical parameters used in the classification criteria for axial (ax) SpA (2). However, it is not used here as an activ...